Burden of HIV-Related cytomegalovirus retinitis in resource-limited settings: A systematic review

Clinical Infectious Diseases

Volumn 57, Issue 9, 2013, Pages 1351-1361

  Ford, Nathan ^a   Shubber, Zara ^b   Saranchuk, Peter ^c   Pathai, Sophia ^d   Durier, Nicolas ^e   O'Brien, Daniel P ^c,f   Mills, Edward J ^g   Pascual, Fernando ^h   Hoen, Ellen T ⁱ   Holland, Gary N ^j   Heiden, David ^k,l  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Foundation for AIDS Research   (Thailand)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF OTTAWA   (Canada)

^h MEDICINES PATENT POOL   (Switzerland)

ⁱ Independent Consultant on Energy and Nuclear Policy   (France)

^j JULES STEIN EYE INSTITUTE   (United States)

^k CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^l Seva Foundation   (United States)

more..

Author keywords

cytomegalovirus; HIV; resource limited settings; retinitis

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; CYTOMEGALOVIRUS RETINITIS; EYE EXAMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; INDIA; LOWEST INCOME GROUP; META ANALYSIS; MIDDLE INCOME GROUP; MORTALITY; MYANMAR; NIGERIA; OPHTHALMOLOGIST; OPHTHALMOSCOPY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETINA EXAMINATION; SOCIAL STATUS; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; THAILAND; VISUAL IMPAIRMENT;

CYTOMEGALOVIRUS; HIV; RESOURCE-LIMITED SETTINGS; RETINITIS;

AFRICA; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ASIA; CYTOMEGALOVIRUS RETINITIS; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; PREVALENCE;

EID: 84886908491     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit494     Document Type: Article

References (40)

1. Kuppermann BD, Petty JG, Richman DD, et al. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 1993; 115:575-82.
2. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166:1223-7.
3. Wallace JM, Hannah J. Cytomegalovirus pneumonitis in patients with AIDS. Findings in an autopsy series. Chest 1987; 92:198-203.
4. Brantsaeter AB, Liestol K, Goplen AK, Dunlop O, Bruun JN. CMV disease in AIDS patients: Incidence of CMV disease and relation to survival in a population-based study from Oslo. Scand J Infect Dis 2002; 34:50-5.
5. Jabs DA, Green WR, Fox R, Polk BF, Bartlett JG. Ocular manifestations of acquired immune deficiency syndrome. Ophthalmology 1989; 96:1092-9.
6. Yust I, Fox Z, Burke M, et al. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: A EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 2004; 23:550-9.
7. Drew WL. Cytomegalovirus disease in the highly active antiretroviral therapy era. Curr Infect Dis Rep 2003; 5:257-65.
8. Joint United Nations Programme on HIV/AIDS. UNAIDS report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS, 2012.
9. Resnikoff S, Felch W, Gauthier TM, Spivey B. The number of ophthalmologists in practice and training worldwide: A growing gap despite more than 200,000 practitioners. Br J Ophthalmol 2012; 96:783-7.
10. Pathai S, Gilbert C, Weiss HA, McNally M, Lawn SD. Differing spectrum of HIV-associated ophthalmic disease among patients starting antiretroviral therapy in India and South Africa. Trop Med Int Health 2011; 16:356-9.
11. Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: The neglected disease of the AIDS pandemic. PLoS Med 2007; 4:e334.
12. The World Bank, Country and Lending Groups. http://data.worldbank. org/about/country-classifications/country-and-lending-groups. Accessed 8 August 2013.
13. Njeru DG, Mwanda WO, Kitonyi GW, Njagi EC. Prevalence of cytomegalovirus antibodies in blood donors at the National Blood Transfusion Centre, Nairobi. East Afr Med J 2009; 86(12 suppl):S58-61.
14. Wiselka MJ, Nicholson KG, Rowley S, Bibby K. Cytomegalovirus viraemia has poor predictive value for the development of cytomegalovirus disease in patients with advanced HIV-infection. J Infect 1999; 39:187-92.
15. Freeman M, Tukey J. Transformations related to the angular and the square root. Ann Inst Stat Mathematics 1950; 21:607-11.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
18. Akinsola F, Hassan M, Soneye-Vaughan O, Majekodunmi A, Adefule- Ositelu A, , Onakoya A. Ocular manifestations of HIV/AIDS at a tertiary institution in Lagos, Nigeria. In: XVI International AIDS Conference, Toronto, Canada, 2006. Abstract CDB0218.
19. Ebana Mvogo C, Ellong A, Bella AL, Luma H, Achu Joko H. Ocular complications of HIV/AIDS in Cameroon: Is there is any correlation with the level of CD4 lymphocytes count? [in French]. Bull Soc Belge Ophtalmol 2007; 7-12.
20. T/Giorgis A, Melka F, G/Mariam A. Ophthalmic manifestation of aids in Armed Forces General Teaching Hospital, Addis Ababa. Ethiop Med J 2007; 45:327-34.
21. Sugar EA, Jabs DA, Ahuja A, Thorne JE, Danis RP, Meinert CL. Incidence of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 2012; 153:1016-24. e5.
22. Kiertiburanakul SBD, Po Lee M, Omar S, et al. TREAT Asia HIV Observational Databases and TREAT Asia Studies to Evaluate Resistance. Time trends of CD4 cell count levels at the initiation of ART among Asian HIV+ patients. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 3-6March 2013. Abstract 1089.
23. Curtis AJ, Marshall CS, Spelman T, et al. Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings. PLoS One 2012; 7:e52019.
24. Holland GN, Vaudaux JD, Jeng S, Yu F, et al.; on behalf of the UCLA CMV retinitis study group. Characteristics of untreated AIDS-related cytomegalovirus retinitis. I. Findings before the era of highly active antiretroviral therapy (1988 to 1994). Am J Ophthalmol 2008; 145:5-11.
25. Compston LI, Li C, Sarkodie F, Owusu-Ofori S, Opare-Sem O, Allain JP. Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa. J Med Virol 2009; 81:1860-8.
26. Cox JA, Lukande RL, Lucas S, Nelson AM, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev 2010; 12:183-94.
27. Jaffar S, Ariyoshi K, Frith P, et al. Retinal manifestations of HIV-1 and HIV-2 infections among hospital patients in The Gambia, West Africa. Trop Med Int Health 1999; 4:487-92.
28. Maartens G. Opportunistic infections associated with HIV infection in Africa. Oral Dis 2002; 8(suppl 2):76-9.
29. Anon. Global HIV/AIDS response: Epidemic update and global progress towards universal access. World Health Organization, UNAIDS, UNICEF, Geneva, 2011.
30. Jabs DA, Holbrook JT, Van Natta ML, et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 2005; 112:771-9.
31. Binquet C, Saillour F, Bernard N, et al. Prognostic factors of survival of HIV-infected patients with cytomegalovirus disease: Aquitaine Cohort, 1986-1997. Groupe d?Epidemiologie Clinique du SIDA en Aquitaine (GECSA). Eur J Epidemiol 2000; 16:425-32.
32. Durier N, Ananworanich J, Apornpong T, et al. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: Prevalence and associated mortality. Clin Infect Dis 2013; 57:147-155.
33. Fielding K, Koba A, Grant AD, et al. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. PLoS One 2011; 6:e25571.
34. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: Systematic review. Trop Med Int Health 2010; 15(suppl 1):1-15.
35. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resourcelimited settings: Systematic review and meta-analysis. PLoS One 2009; 4:e5790.
36. Saranchuk P, Bedelu M, Heiden D. Retinal examination can help identify disseminated tuberculosis in patients with HIV/AIDS. Clin Infect Dis 2013; 56:310-2.
37. Johnson LF, Mossong J, Dorrington RE, et al. Life expectancies of South African adults starting antiretroviral treatment: Collaborative analysis of cohort studies. PLoS Med 2013; 10:e1001418.
38. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med 1996; 334:1491-7.
39. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solidorgan transplants: A systematic review of randomised controlled trials. Lancet 2005; 365:2105-15.
40. Zhou F, Kominski GF, Qian HZ, et al. Expenditures for the care of HIV-infected patients in rural areas in China?s antiretroviral therapy programs. BMC Med 2011; 9:6.